The present study examines the possible effect of the glucosylxanthone mangiferin (MG) on pain-related behaviors in a tonic acute pain model (formalin test at 5%) and in a chronic constriction injury (CCI) model to clarify the underlying transient and long-term mechanisms. Acute administration of MG (10-100 mg/kg, i.p.) reduced licking/biting exclusivity in the tonic phase of formalin test in a naloxone and yohimbine-sensitive manner. This effect was enhanced by a nonselective nitric oxide synthase (NOS) inhibitor (NG-monomethyl-L-arginine) and by a non-competitive N-methyl-D-aspartate (NMDA) antagonist (ketamine), but it was reversed by the NOS substrate (L-arginine). Pre-treatment with intrathecal yohimbine prevented the anti-hypernociceptive effect of systemic MG. Pre-treatment during 4 days before surgical and 3 days after CCI with MG (50 mg/kg, i.p.) reduced mechanical hypernociception and decreased the signs of Wallerian degeneration (WD) of the sciatic nerve. MG improved the PC-12 cellular viability exposure to glutamate-mediated neuronal death, also involved in neuropathic pain. The findings of this study suggest that MG shows ability to decrease tonic pain in the formalin test. A transient activity of this xanthone on nociceptive pathways mediated by α 2 adrenergic receptors in cooperation with the opioid system could be involved, at least in part, in this effect. Its neuroprotective effect by preventing WD in mononeuropathic rats could be implicated in the mechano-antihypernociceptive long term mechanisms.
Introduction
Mangiferin (MG) is a glucosylxanthone broadly distributed in higher plants such as Mangifera indica L. (Anacardiaceae) (Núñez-Sellés et al., 2002) . This compound is frequently used in traditional medicine and exhibits numerously biological activities (García et al., 2002; Garrido et al., 2004; Pardo-Andreu et al., 2008) . Most of these effects are explained, at least in part, by inhibition of NF-κB pathway activation (Leiro et al., 2004a) . NF-κB induces the transcription of genes implicated in the expression of some mediators and enzymes involved in inflammation, pain, oxidative stress and synaptic plasticity as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) (Wei et al., 2007; Lin et al., 2007) . In addition, MG shows neuroprotective effects in the glutamate induced neurotoxicity in rat cerebral cortex neurons, preventing neuronal death, oxidative stress and mitochondrial depolarization (Gottlied et al., 2006; Lemus-Molina et al., 2009) . This xanthone modulates the activity of the Art and Erk1/2 kinases and neuronal NF-κB nuclear translocation, inhibits calpain activity and maintains the homeostasis of the antioxidant systems after an excitotoxic event (Campos-Esparza et al., 2009) . Particularly, MG decreases the glutamate-mediated Ca 2+ influx through N-methyl-D-aspartate (NMDA) receptor (Gottlied et al., 2006) . Also, in view of the relevance of glial activation in neurodegenerative disorders, MG is able to limit microglial activation in terms of attenuation of prostaglandins E 2 (PGE 2 ) production, reactive oxygen species (ROS) formation and reduction of cyclooxygenase-2 (COX-2) synthesis induced by lipopolysaccharide (Bhatia et al., 2008) . These evidences suggest the potentiality of this compound to modulate some of the molecular targets implicated in neuropathic pain mechanisms, especially central sensitization, through of its long term effects mediated mainly by transcriptional changes (Garrido-Suárez et al., 2010) . Previously, we advised that MG could be used to treat neuropathic pain supported in these preclinical data and some preliminary clinical reports with M. indica L. extract formulations that contain 15-20% of this polyphenol (Garrido-Suárez et al., 2010 , 2011 . Given that neuroimmune activation, oxidative stress and neuroprotection have been proposed as a new target for its therapeutic intervention (Kim et al., 2004; De Leo et al., 2006; Gao et al., 2007; Bordet and Pruss, 2009 ). Nevertheless, a transient mechanism of MG on nociceptive pathway could be implicated and the participation of endogenous opioids, K ATP channels and adenosine in acute models of chemical nociception, including formalin test at 1%, is reported (Lopes et al., 2013) . On the other hand, a reversible mono-amine oxidase (MAO) inhibitory activity by MG is recognized (Tomić et al., 2005) and its favorable effect on long-term object recognition memory in rats (PardoAndreu et al., 2010) could be explained, at least in part, by the modulation of the noradrenergic system also involved in pain transmission. In addition, several lines of evidence have indicated that in the central nervous system, nitric oxide (NO) interacts with noradrenergic mechanisms involved in descending inhibitory pathways, and a reciprocal interplay between NO and α 2 -adrenoreceptor in the inhibition of pain in the dorsal horn of the spinal cord has been observed (Xu et al., 1997) . Conversely, NO is pivotal in central sensitization and at this time, it recognizes its dual effect on pain transmission and control (Vetter et al., 2001; Cury et al., 2011) . L-Arginine-NO-cGMP-sensitive K ATP channel pathway mediates the peripheral and central antinociceptive effect of several compounds such as opioids, non-steroidal anti-inflammatory drugs, α 2 -adrenoreceptor agonists as clonidine and plant extracts, in which the most commonly found chemical compounds are natural polyphenols (Cury et al., 2011; Ebrahimi and Schluesener, 2012) . Recently, this peripheral mechanism has been reported for MG (Izquierdo et al., 2013) . The aim of the present study was to evaluate the effect of acute systemic administration of MG in rats on pain-related behaviors in tonic acute pain model (formalin test at 5%), the recommended model when studying antinociceptive activity of NO-and NMDA-related compounds since formalin evoked spinal release of nitrite/nitrate and glutamate in correlation with the biphasic behavior (Okuda et al., 2001) , as well as to introduce the study of this xanthone for the first time in chronic constriction injury (CCI) in rats to clarify the underlying transient and long-term mechanism with its subsequent clinical relevance. Additionally, the neuroprotective effect of MG probably implicated in its underlying mechanisms in CCI model was examined in in vitro model for studying glutamatergic neurotoxicity.
Material and methods

Drugs
Mangiferin (2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one) was supplied by the Laboratory of Analytical Chemistry, Center of Pharmaceutical Chemistry (Cuba) and had been isolated from the M. indica stem bark standardized extract by extraction with methanol yielding a yellow powder with 90% purity as determined by high performance liquid chromatography (HPLC) (Núñez-Sellés et al., 2002) . MG was suspended in DMSO (5% in saline solution) for intraperitoneal administration. The solution DMSO + saline has been shown to have no effects on nociception (Colucci et al., 2008) . Naloxone hydrochloride, morphine hydrochloride, clonidine hydrochloride, yohimbine hydrochloride, (±)-2.5-dimethoxy-4-iodoamphetamine (DOI), methysergide maleate, NG-monomethyl-L-arginine (L-NMMA), L-arginine and ketamine hydrochloride were purchased from Sigma Chemical Co., St. Louis, MO, USA. Formaldehyde was obtained from Merck (Darmstadt, Germany). All these compounds were dissolved in saline 0.9%.
Experimental animals
Experimental procedures were carried out in accordance with European regulations on animal protection (Directive 86/609), the Declaration of Helsinki, and/or the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . All experimental protocols were approved by the Institutional Animal Care and Ethical Committee from the Center of Drugs Research and Development (CIDEM, La Habana, Cuba). Male Sprague-Dawley (8-10 weeks) rats weighing 200-250 g were obtained from the Center for Experimental Animals Production (CENPALAB, La Habana, Cuba). They were kept in controlled conditions (22 ± 0.5°C, relative humidity 40-60% a 7 a.m. to 7 p.m. alternate light-dark cycle, food and water ad libitum). The experiments took place during the light period and animals belonging to the various treatment groups (n = 6-10 for each group) were tested in randomized order.
Formalin test. Acute spontaneous nociceptive behavior
The rats were placed individually in an open glass cylindrical chamber (34 × 30 × 28 cm). The animals were habituated to the chamber for 20 min prior to the injection, and returned to the camera following the injection for their observation. Twenty minutes before the formalin injection rats received a single intraperitoneal dose of MG (10, 50, 100 mg/kg, dose volume 1 mL/kg, i.p.) or vehicle (DMSO 5% in saline solution). Formalin (50 μL, s.c.) was inserted into the plantar surface of the right hindpaw of the rat using a microsyringe with a 26-gauge needle (Dubuisson and Dennis, 1977) . Licking/biting of the injected paw was recorded using a digital chronometer as the total licking/biting time (s) per 5 min observation periods for 45 min after formalin injection. The response curves for formalin-induced licking/biting behaviors were generated by recording early (0-5 min), latency (5-15 min) and late (15-45 min) phases (Okuda et al., 2001 ).
2.3.1. Pre-treatment with opioid, alpha 2 noradrenergic and serotonergic receptor antagonists before a single dose of mangiferin in the formalin test
Rats were pre-treated with naloxone (0.1-1 mg/kg, i.p.) a nonselective antagonist of opioid receptors; yohimbine (0.1-1 mg/kg, i.p.) a selective α 2 adrenoreceptor antagonist and methysergide (1-5 mg/kg, i.p.) a nonselective 5-HT receptor antagonist or vehicle. After 15 min, the animals received a dose of MG (100 mg/kg, i.p.) or vehicle, 20 min before formalin injection. Morphine 5 mg/kg, clonidine 0.1 mg/kg and DOI 1 mg/kg were used as positive control, respectively. The agonist and antagonist drugs and doses were selected according to the previous reports (Ahsana et al., 2005; Jürgensen et al., 2005) and on pilot experiments in our laboratory.
2.3.2. Pre-treatments with NOS inhibitor, NOS substrate and NMDA antagonist on tonic phase of formalin test before mangiferin Rats were pre-treated with NG-monomethyl-L-arginine (L-NMMA) (3-30 mg/kg or vehicle, i.p.) a nonselective inhibitor of nitric oxide synthase (NOS). After 15 min, the animals received an injection of MG (100 mg/kg or vehicle, i.p.). Following 20 min, formalin s.c. was injected. Other groups of animals were included to perform similar protocol but received pre-treatment with L-arginine (100-300 mg/kg, i.p.) the substrate to NOS, low dose of ketamine (0.3-1 mg/kg, i.p.) a non-competitive NMDA antagonist or their corresponding vehicles.
2.3.3. Pre-treatment with intrathecal yohimbine and L-NMMA before single systemic mangiferin in the formalin test Additionally, to assess the possible participation of spinal α 2 adrenoreceptor in the systemic action of MG, an intrathecal injection of yohimbine (3-10 μg/20 μL) or vehicle in the same volume (saline) was administered 5 min before MG (100 mg/kg, i.p.). After 20 min intraplantar formalin was administered in right hindpaw. Other groups were performed to verify the involvement of L-arginine-NO pathway in a possible spinal noradrenergic mechanism of systemic MG. The rats received intrathecal injection of L-NMMA (10-20 μg/20 μL) or vehicle (saline) following similar protocol. Intrathecal injections were performed by L6 lumbar puncture under brief anesthesia with ether, whereby intrathecal delivery was confirmed by observing an injection induced tail-flick (Mestre et al., 1994) .
Neuropathic surgery (chronic constriction injury, CCI)
Animals were anesthetized with xylazine (13 mg/kg, i.m.) and ketamine (87 mg/kg, i.m.). A CCI was produced by ligating the common sciatic nerve on the left side (Bennett and Xie, 1988) . Briefly, the common sciatic nerve was exposed at the level of the middle of the thigh by blunt dissection through the biceps femoris. Proximal to its trifurcation, about 7 mm of nerve was freed of adhering tissue and three ligatures (using 4.0 chromic gut) were tied loosely around it at 1-1.5 mm intervals. The ligatures just barely constricted the diameter of the nerve when viewed by 40×magnification. This degree of constriction retarded, but did not arrest, the circulation through the superficial epineural vasculature and produced a small, brief twitch in the muscle around the exposure. The incisions were closed in layers. In sham-operated controls, an identical operation was performed but without ligation of the sciatic nerve. The animals were divided into three groups of ten rats each: Control CCI group that received i.p. injection of vehicle (DMSO 5% in saline solution), experimental CCI-MG group that received MG (50 mg/kg, i.p.) and sham CCI also treated with vehicle. In all cases, the medication was administered in 7 days (4 days before surgery and 3 days after CCI).
Hindpaw mechano-hypernociception
Mechano-hypernociception of the hindpaw was assessed using a modification of the pin prick method (Tal and Bennett, 1994) . With the rats standing on the wire mesh floor and restricted beneath an inverted plastic box (described above), the point of a blunted 23 gauge needle was applied to the skin of the heel (touching, but not penetrating). Normal rats respond with a tiny and brief withdrawal. CCI rats respond most often with a withdrawal that is clearly exaggerated in amplitude and duration. Behavioral responses to the pin prick were rated according to the following scale: 0 = no response; 1 = rapid paw flicking, stamping, or shaking (less than 1 s); 2 = repeated paw stamping, shaking, or paw lift less than 3 s; 3 = above behaviors or hindpaw licking for more than 3 s; 4 = above behaviors for more than 3 s and hindpaw licking for more than 3 s. An additional point was added if any vocalizations occurred.
Cell cultures and PC12 neuronal cell viability assay (glutamatemediated injury)
Stock cultures of PC12 cells (Rockville, MD) were grown on polystyrene tissue culture dishes in RPMI-1640 supplemented with 10% horse serum, 5% fetal bovine serum, and 100 units/mL penicillin, 100 μg/mL streptomycin in 37°C incubator in 5% CO 2 in a humidified atmosphere. The medium was changed every 2-3 days, and cells were incubated in serum-free RPMI-1640 medium for 24 h before treatment with L-glutamate 50 mmol/L. Cells were plated onto 96-well plate (1 × 10 5 cells/mL) (Choi, 1988) . Different concentrations of MG were previously pre-incubated for 24 h before glutamate addition (and maintained during glutamate exposure). Then, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) solution (0.4 mg/mL) was added and incubated for 4 h at 37°C and centrifuged at 400 ×g for 5 min. The resulting supernatant was discarded, and 100 μL of DMSO was added. After shaking the plates for 10 min, the optical density was immediately measured at 570 nm. Values were expressed as the percentage of viable cells (Mosmann, 1983) .
Histopathological studies
Samples of 5 mm sciatic nerve located distal to the lesion were stored in the fixative solution (10% formalin) and cut into 4 μm thickness. Staining was carried out by using hematoxylin and eosin (Sudoh et al., 2004) . Nerve sections were analyzed qualitatively under light microscope (40×) for axonal degeneration.
Motor coordination
To evaluate the possible occurrence of non-specific effects such as muscle-relaxation or sedation, the effect of mangiferin on motor coordination was assessed in rats submitted to the rota-rod test (Rosland et al., 1990) . The apparatus consisted of a bar with a diameter of 2.5 cm, subdivided into four compartments. The bar rotated at a constant speed of 22 r.p.m. and animals were evaluated for the time spent to fall from the bar. The animals were treated with MG 10, 50 and 100 mg/kg, i.p. or vehicle at the same volume 1 mL/kg, 20 min before being tested. The cut-off time used was 60 s.
Statistical analysis
Data were analyzed using the statistical program Graph Pad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Inter-group statistically significant differences were tested using one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc test for multiple comparisons. The results are presented as mean ± SEM. P b 0.05 was considered statically significant.
Results
Effect of mangiferin on licking/biting behaviors in the formalin test at 5%
5% formalin was injected into the plantar surface of the right hindpaw produced a typical pattern of licking/biting behavior characterized by a biphasic time course (Fig. 1A) . In formalin test, mangiferin (50 and 100 mg/kg) reduced the mean of cumulative licking/biting times (s/5 min) exclusivity during phase II (tonic inflammatory pain) compared with vehicle pre-treated controls (phase II: vehicle = 556 ± 32, MG50 = 232 ± 19, P b 0.01, MG100 = 75 ± 25, P b 0.001). By contrast MG was ineffective in showing significant change on phase I nociceptive activity compared with vehicle controls (phase I: vehicle = 90 ± 7, MG50 = 90 ± 13, MG100 = 49 ± 2) (Fig. 1B). 3.2. Effect of pre-treatment with opioid, alpha 2 noradrenergic and serotonergic receptor antagonists before a single dose of mangiferin in the formalin test
The results presented in Fig. 1C show that the pre-treatment of rats with yohimbine (1 mg/kg, i.p.) 15 min before, significantly returned the anti-hypernociception caused by clonidine (0.1 mg/kg, i.p.) and MG (100 mg/kg, i.p.) in phase II of formalin test (vehicle = 501 ± 67, clonidine = 123 ± 19, P b 0.001, MG100 = 46 ± 22, P b 0.001, yohimbine + clonidine = 436 ± 63, P b 0.001, yohimbine + MG100 = 338 ± 70, P b 0.001). As shown in Fig. 1D , naloxone (1 mg/kg, i.p.) partially reversed the effect of MG compared with morphine (5 mg/kg, i.p) in this phase since the rats treated with naloxone + MG yet showed less nociceptive behaviors compared with controls (vehicle = 556 ± 32, morphine = 125 ± 18, P b 0.001, MG100 = 75 ± 25, P b 0.001, naloxone + morphine = 488 ± 50, P b 0.001, naloxone + MG100 = 381 ± 76, P b 0.001). However, the pre-treatment with methysergide (5 mg/kg, i.p.) a non-selective 5-HT receptor antagonist significantly reversed the effect of DOI (1 mg/kg, i.p.) a serotonergic agonist with respect to controls, but did not significantly change the antihypernociception produced by MG expressed as the cumulative mean of licking/biting during this phase (vehicle = 469 ± 42, DOI = 175 ± 40, P b 0.001, MG100 = 193 ± 73, P b 0.001, methysergide + DOI = 405 ± 45, P b 0.001, methysergide + MG100 = 205 ± 49) (Fig. 2). 3.3. Effects of pre-treatment with NOS inhibitor, NOS substrate and NMDA antagonist (modulators of NMDA-NO pathway) in the effect of mangiferin on tonic phase of the formalin test
The results presented in Fig. 3 show the pre-treatment with L-NMMA (3-30 mg/kg, i.p.), a non-selective NOS inhibitor and (MG 100 mg/kg, i.p.). The high dose (30 mg/kg) reduced the cumulative mean of licking/biting during phase II compared with vehicle controls (vehicle = 526 ± 50, L-NMMA = 210 ± 32, P b 0.001, MG100 = 139 ± 41, P b 0.001). The pre-treatment with L-NMMA (30 mg/kg) prior to MG significantly enhanced the antihypernociceptive effect of MG (L-NMMA + MG100 = 18 ± 4, MG100 = 139 ± 41, P b 0.05). The nitric oxide precursor L-arginine (300 mg/kg, i.p.) increased the nociceptive behavior in phase II of formalin test compared with vehicle treated animals (vehicle = 501 ± 67, L-arginine = 640 ± 23, P b 0.01). Its administration 15 min before MG (100 mg/kg, i.p) reversed MG decreased licking/biting response in this phase (vehicle = 501 ± 67, MG100 = 52 ± 14, P b 0.01, L-arginine + MG100 = 363 ± 70, P b 0.05). Ketamine, a non-competitive NMDA antagonist was utilized at low doses (0.3 and 1 mg/kg, i.p was ineffective for reducing licking/biting behavior in the tonic phase (vehicle = 554 ± 45, ketamine = 467 ± 20, P N 0.05)). Nevertheless, its administration at dose of 1 mg/kg 15 min before MG (100 mg/kg, i.p.) significantly improved the anti-hypernociceptive effect of MG (vehicle = 554 ± 45, MG100 = 132 ± 42, P b 0.001, ketamine + MG100 = 36 ± 20, P b 0.05). 3.4. Effects of pre-treatment with intrathecal yohimbine and L-NMMA in the effect of single systemic mangiferin on tonic phase of the formalin test
The previous treatment with intrathecal yohimbine (10 μg/20 μL), given 5 min before systemic MG (100 mg/kg, i.p.) significantly reversed the anti-hypernociceptive effect of MG in phase II of formalin test (vehicle = 393 ± 55, MG100 = 58 ± 21, P b 0.001, yohimbine + MG100 = 225 ± 42, P b 0.05) (Fig. 4A) . Nevertheless, L-NMMA at 20 μg/20 μL given 5 min before systemic MG was ineffective for reversing its effect. In contrast, the NOS inhibitor significantly enhanced the antihypernociceptive effect of this xanthone and the cumulative mean of licking/biting behavior was minimal in animals pre-treated with L-NMMA (vehicle = 393 ± 55, MG100 = 58 ± 21, P b 0.001, L-NMMA + MG100 = 4 ± 1, P b 0.05) (Fig. 4B) . increase of nociceptive responses to pin prick (nociceptive score) when compared to the sham group at 7 and 14 days (Fig. 5 ). Pre-treatment during 4 days before surgical and 3 days after CCI with MG (50 mg/kg, i.p.) significantly attenuated CCI induced nociceptive responses to pin prick at 7 days (P b 0.05) and 14 days (P b 0.01). In addition, CCI caused abnormal histopathological changes seen by light microscopy in longitudinal section of the sciatic nerve undergoing Wallerian degeneration. The cellularity increased in relation with sham CCI as the result of Schwann cell proliferation and macrophage infiltration. The fragmentation of myelin sheath into myelin ovoids, which are contained in the Schwann cell cytoplasm (digestion chambers) and the axonal degeneration, which resulted in a loss of the orderly alignment of axons, were observed ( Fig. 6A and B ). The treatment with MG (50 mg/kg, i.p.) attenuated CCI-induced Wallerian degeneration-related changes (Fig. 6C ).
Effect of mangiferin on mechanical hypernociception and histopathological changes in chronic constriction injury model
Effect of mangiferin on in vitro model for studying glutamatergic neurotoxicity
MTT assay showed that the viability of rat pheochromocytoma (PC12) cells was inhibited by 50 mM L-glutamate by about 48%. Pretreatment with MG 100 and 250 μg/mL improved the viability of PC12 cell between 61 and 71%, respectively (P b 0.01 and P b 0.001) (Fig. 7) .
A possible sedative or anesthetic effect of mangiferin
Since sedation or anesthesia could raise mechanical thresholds, it was necessary to determine if these contributed to the behavioral changes interpreted as analgesia. MG (10, 50 and 100 mg/kg, i.p.) failed to produce significant effect on motor coordination on rota-rod in rats, showing that the anti-hypernociception was unrelated to sedation or motor coordination.
Discussion
The most relevant finding of this study is that MG decreases painrelated behaviors (licking/biting), unrelated to sedation or motor coordination, exclusively in the tonic phase of formalin test at 5%, which has been considered as being due to inflammatory components, peripheral and central sensitization (Coderre et al., 1990) . This antecedent is an element that suggests its capacity to modulate pathological and persistent painful status more than acute nociceptive pain. In these conditions, the Ca 2+ influx induced for NMDA activity triggers enzymatic cascades. This event at last also evoke the release of postsynaptic NO and prostaglandins, that in turn further increase presynaptic glutamate release leading to an ongoing activity in primary afferents, increased sensitivity of dorsal horn neurons and finally allow central sensitization (Vetter et al., 2001; Latremoliere and Woolf, 2009 ). Subsequently, the selective effect that shows COX and NOS inhibitors and NMDA antagonists in this phase is known (Latremoliere and Woolf, 2009) . It has been reported that MG decreased the glutamatemediated Ca 2+ influx during NMDA receptor activation in neurons, a fact that suggested a modulation of this process by this xanthone (Gottlied et al., 2006; Garrido-Suárez et al., 2010) . In addition, it has been established that ROS play an important role in the phosphorylation of NMDA receptor subunit 1 (pNR1) in the spinal cord, as well spinal ROS constituted the key mediating phase II in a formalin test (Hacimuftuoglu et al., 2006; Gao et al., 2007) . MG exhibits a potent antioxidant effect depending on its free radical scavenging (Garrido et al., 2008) and iron-complexing abilities (Pardo-Andreu et al., 2008 ) that could explain its main effects on phase II.
In congruence with this idea, both a non-selective NOS inhibitor and a non-competitive NMDA antagonist injected prior to MG enhanced its inhibitory effect on tonic phase. Additionally, this effect was reversed by the NOS substrate L-arginine. These evidences suggest any favorable interaction between MG and NO-and NMDA-related compound in the tonic phase of this test. MG decreases iNOS mRNA and iNOS protein levels in inflammatory peritoneal macrophages, as well as NO production in several studies (Leiro et al., 2004b; García et al., 2002) .
Recent reports show that MG, similar to NMDA blockers as ketamine, failed to modify the thermal nociception in hot-plate and tailflick, assessed in no-injured animals in which these mechanisms are not triggered (Bulutcu et al., 2002; Latremoliere and Woolf, 2009; Lopes et al., 2013) . However, at present there are no evidences that display the direct action of MG on spinal glutamate-NMDA-NO-cGMPprotein kinase G-I (PKG-I) pathway pivotal in hyperalgesic states.
In order to elucidate a direct effect of MG in the regulation of nociceptive pathways via descending control circuits implicated in the formalin test, we evaluated the possible contribution of the opioidergic, noradrenergic and serotonergic systems (Wu et al., 2001; Xu et al., 1997; Omote et al., 1998) .
Our experiment showed that systemic MG decreases licking/biting supra-spinal behavior in phase II, in a naloxone-sensitive manner, similar to that reported in acute models of chemical nociception in mice, suggesting the participation of endogenous opioids in its mechanism (Lopes et al., 2013) . Previously, the inhibition of acetic acid induced pain by MG isolated of Bombax ceiba L. extract and its partial reversion by naloxone was also observed (Ahsana et al., 2005) . Recently, the role of peripheral opioidergic system involving the activation of δ, κ, and μ opioid receptors, in the analgesic mechanism of MG has been demonstrated in this test (Izquierdo et al., 2013) .
However, a central and peripheral cooperative effect between opioid and adrenergic systems has been reported (Nakamura and Ferreira, 1988; Xu et al., 1997) . MG and other xanthones inhibit MAO activity, an effect that could enhance catecholamine concentration in the synaptic cleft modulating spinal nociceptive processing through the periaqueductal gray/rostroventromedial medulla/dorsolateral pontine tegmentum (PAG/RVM/DLPT) descending modulatory network (Tomić et al., 2005) .
For the first time, this study reports that the anti-hypernociceptive effect of systemic MG in formalin test could be mediated at last in part via α 2 adrenergic receptors; in addition, these spinal receptors could be implicated. Nevertheless, MG also could mediate its actions through of the peripheral α 2 adrenergic receptors (Nakamura and Ferreira, 1988) given that it has been reported that MG cannot traverse the Digital Version Printed Version blood-brain barrier after being administered systemically in rats. The authors propose that its beneficial effects are dependent of its peripheral functions, along with MAO inhibition, which should lead to enhanced availability of amines in the periphery that in consequence translate central secondary manifestations (Zajac et al., 2013) . However, the potential role of MG aglycone (norathyriol) or another metabolite perhaps more bio-available should be considered (Hsu et al., 1997) .
On the other hand, NO is involved in descending system, and a reciprocal interplay between NO and α 2 -adrenoreceptor in the inhibition of pain in the dorsal horn of the spinal cord has been observed (Xu et al., 1997; Cury et al., 2011) , but the anti-hypernociceptive effect of MG was not reversed by L-NMMA; on the contrary decreased the nociceptive behavior even more. This conflicting result may be explicated by dual role of spinal NO, which in inflammatory circumstances is pronociceptive (Rivot et al., 2002; Salvemini et al., 2011) . Synergistic effect with opioids and decreased inflammatory and neuropathic hyperalgesia after spinal and systemic injections of NOS inhibitors have also been reported (Malmberg and Yaksh, 1993; Yamaguchi and Naito, 1996) .
The heterogeneous nature of the serotonin (5-HT) receptor family and the multiplicity of neuronal targets underlie the bidirectional effect of the neurotransmitter. The antinociception of DOI, a mixed 5-HT 2A / 2C receptor agonist in the formalin test, has been reported, and this effect was blocked by methysergide that mainly antagonizes these 5-HT 2 receptor subtypes (Sasaki et al., 2001) . But in congruence with other report, the anti-hypernociception caused by MG was independent of the serotonergic system (Izquierdo et al., 2013) ; however, in both studies (including the present one) utilized a non-selective antagonist. Nowadays, the evidence mainly points to a pronociceptive role of the 5-HT 2A ; however an antinociceptive effect has been reported for the 5-HT 2C subtype receptor in modulating spinal nociceptive transmission (Suzuki et al., 2004) .
Another important feature was the first approach to the study of this xanthone in a CCI neuropathic pain model (Bennett and Xie, 1988) . Systemic administration of MG prevented the mechano-hypernociception on ipsilateral paw during the severity peaking at 7 and 14 days. MG also attenuated CCI-induced Wallerian degeneration (WD) related changes. This process is tightly linked to the development of neuropathic pain following CCI (Ramer et al., 1997) .
Recent evidence indicates that the main pathogenic mechanism in CCI is the neuroinflammation (Berger et al., 2011) . WD involves an increase in free intracellular Ca 2+ and the activation of calpains leading to a massive decrease of microtubular and neurofilament protein levels and to axonal fragmentation within 48 h (Berger et al., 2011; Debový, 2011) . The MG inhibition of calpain activity could be implicated in its beneficial effect by reduced WD and subsequent mechanical hypernociception (Campos-Esparza et al., 2009) . Some cytokines as tumor necrosis factor alpha (TNFα) have been implicated in both thermal and mechanical hyperalgesia, as well as inducing long-term potentiation in spinal dorsal horn via NF-κB in nerve injured rats (Wei et al., 2007; Lin et al., 2007) . MG also primarily inhibits TNFα-induced activation of NF-κB (Leiro et al., 2004a; Garrido et al., 2004) . On the other hand, neuronal apoptosis in a small subpopulation of cell has been reported in the dorsal horn after CCI; afterwards, selective neuronal loss may contribute to pain hypersensitivity through the temporary loss of inhibitory neurons (Whiteside and Munglani, 2001; Latremoliere and Woolf, 2009 ). This neuronal death appears to be the result of an NMDA receptor-induced excitotoxicity in addition to nitroxidative stress.
The current results in an in vitro model for studying glutamatergic excitotoxicity in PC12 cells demonstrate the neuroprotective effect of MG. Since there are only limited functional responses to NMDA/glutamate recently reported in this model, it is more rational to consider that MG prevents PC12 cell death by reducing oxidative stress, given that high levels of glutamate lead to inhibition of cysteine uptake and intracellular glutathione (GSH) depletion (Edwards et al., 2007; Salvemini et al., 2011) . MG can restore the GSH content (Ebrahimi and Schluesener, 2012) and it shows in vitro neuroprotective mechanisms (Gottlied et al., 2006; Lemus-Molina et al., 2009 ). These facts make this molecule an attractive multi-target compound with potentiality to prevent and treat neuropathic pain, when potential barrier to peripherally or centrally restricted drugs is removed in the context of nerve injury.
Taken all together, the present results suggest that MG exhibits an anti-hypernociceptive action on tonic pain model that could have clinical relevance in neuropathic pain, where underlying central sensitization is pivotal. A transient activity of this xanthone on nociceptive pathways mediated by spinal α 2 adrenergic receptors in cooperation with the opioid system could be involved, at least in part, in this effect. Its neuroprotective effects by preventing WD in mononeuropathic rats could be implicated in the mechano-antihypernociceptive long term mechanisms.
